Novartis Ranked Among Top 10 SAFE International Dividend Stocks For Income Investors
By Dividend Channel Staff, Thursday, April 9, 10:08 AM ETAccording to the ETF Finder at ETF Channel, Novartis is an underlying holding representing 1.37% of the Powershares International Dividend Achievers ETF (PID), which holds $11,839,817 worth of NVS shares. ETFs such as PID often screen for companies that combine an established dividend record with balance-sheet strength, so inclusion in the portfolio reinforces the company's status as a core income holding for globally diversified investors.
Novartis (NYSE:NVS) made the "Dividend Channel International S.A.F.E. 10" list because of these qualities: S. Solid return — a relatively hefty yield and strong DividendRank characteristics, which blend yield, dividend growth, and valuation metrics; A. Accelerating amount — a pattern of consistent dividend increases over time; F. Flawless five year history — no missed or lowered dividend during the screened period; E. Enduring — at least a half-decade of uninterrupted dividend payments, indicating resilience across market cycles.
Beyond its dividend profile, Novartis is one of the world's largest pharmaceutical companies by market capitalization, with a diversified portfolio across innovative medicines, oncology, cardiovascular and immunology therapies, as well as certain legacy and mature brands. This diversification, together with a broad geographic footprint and a robust late-stage research and development pipeline, underpins the company's ability to generate recurring cash flows that can support an ongoing capital-return program.
Income-focused investors also tend to look for balance-sheet quality when assessing dividend sustainability. Novartis historically has maintained investment-grade credit ratings, and management has articulated a capital-allocation framework that balances reinvestment in R&D and strategic acquisitions with shareholder returns via dividends and, opportunistically, share repurchases. That framework, combined with relatively stable demand for pharmaceutical products, contributes to the stock's appeal for long-term dividend strategies.
Start slideshow:The annualized dividend paid by Novartis is $4.740247/share, currently paid in annual installments, and its most recent dividend ex-date was on 03/11/2026. For investors, the ex-dividend date determines which shareholders are entitled to the upcoming payout, and the level of the annualized dividend, together with the prevailing share price, drives the indicated yield cited in the Dividend Channel analysis.
The chart below illustrates Novartis's long-term dividend history, highlighting the company's record of raising its payout over an extended period. Consistent growth in the dividend per share, even through periods of market volatility, is often viewed as a signal of underlying earnings strength and disciplined capital allocation.
NVS operates in the Drugs & Pharmaceuticals sector, among companies like Eli Lilly (LLY), and Johnson & Johnson (JNJ). As with its large-cap peers, the company's ability to translate a substantial research budget into commercially successful therapies is central to its long-run earnings and cash-flow trajectory — and, by extension, to the sustainability and potential growth of its dividend. For investors constructing globally diversified income portfolios, Novartis's combination of scale, defensive industry positioning, and a demonstrated commitment to returning cash to shareholders helps explain its inclusion in the International S.A.F.E. 10 list.
See whether the same theme is showing up elsewhere by reviewing Decades of Increasing Payments: 25 S.A.F.E. Dividend Stocks.
